Asthma is an inflammatory disorder that affects between 339 million people worldwide, leading a high economic impact [1].Despite the efficacy of standard therapies, in many casesthey do not manage to mitigate the symptoms; thus, finding new treatments is a permanent challenge. In patients with severe asthma, the emergence of biological medications in the pharmaceutical market has allowed personalized medicine, adjusted to the predominant pathophysiological alterations in each individual [2].
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